KKCG
Technology

KKCG
technology

Our business is built on our inherent strengths – KKCG's size and resources, ability to succeed in new markets, expertise in the IT and biotechnology sectors, and experience with effective management.

Show success stories

1/1 our success

ARICOMA Group continues expansion into international markets

9 companies
in the ARICOMA Group

380 million euros
in consolidated sales

3,500
IT professionals

Our long-term vision is to make the ARICOMA Group an international leader in the provision of IT services. Currently, the Group has more than 1,000 clients in 15 countries and sales of 380 million euros. Its portfolio no longer includes only IT companies such as AUTOCONT, Cleverlance, and AEC, but also other major technology companies such as Seavus, Komix, Stratiteq, and Clearcode. ARICOMA is a partner for big players such as Microsoft, Dell, HP, and other renowned companies, but also for institutions such as the European Commission.

Technology

The cornerstone of the IT pillar is the technology holding company ARICOMA

The ARICOMA Group is the largest Czech IT holding, which is gradually fulfilling its ambition to become a leader on the international market. The Group consists of companies such as AUTOCONT and AEC, but also other IT companies from Sweden, Poland, and other countries. It is succeeding in penetrating new markets in Western Europe. In IT services, ARICOMA covers the entire corporate IT portfolio.

We help startups launch growth and global expansion

The Springtide Ventures fund is a KKCG subsidiary that has been, since 2016, investing in European and Israeli start-ups active in high-growth IT segments, such as cloud, IT security, artificial intelligence, and online trading platforms. It focuses on more advanced projects that already have a product, market fit, and customers. Springtide Ventures has offices in Europe, Israel, and in the US.
KKCG is also one of the major shareholders of JAZZ Venture Partners and its strategic partner for Europe. The fund is based in Silicon Valley, USA, and invests in companies in the Human Performance Technology sector.

We invest in expensive biotechnology

Biotechnology research and the transfer of the results derived from it to the marketplace is a very costly, high-risk enterprise. KKCG is one of a small number of Czech corporations engaged in this area. We develop state-of-the-art medical devices that improve the quality of life for patients.

Our funding provides support for clinical trials of Senescence and MitoTam developed by Professor Jiří Neužil at the Institute of Biotechnology.